Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 20, 2009

moksha8 Broadens Partnership with Roche to Commercialize More Products in Mexico

  • moksha8 expanded its strategic partnership with Roche to commercialize an additional portfolio of products in Mexico, currently generating sales of $140 million.

    moksha8 will commercialize products in three therapeutic areas—CNS disease, anti-infectives, and inflammation. The product portfolio consists of well-known brands including Rivotril®, Rocephin®, and Bactrim®.

    “moksha8 has established a broad footprint in Latin America, with leading products that are cornerstones of medical care,” said Simba Gill, CEO of moksha8. “We look forward to continuing our strong relationship with Roche and driving value from this important portfolio of products.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »